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The role of mouse mast cell protease 4 (mMCP-4) in the in vivo
conversion of Big-ET-1 to ET-1, via the hydrolysis of the inactive
intermediate, ET-1 (1-31), has been recently reported (Houde et al.,
JPET, 2013). Our principal aim was to assess the capacity of mast cell
derived or recombinant mMCP-4 to convert Big-ET-1 to ET-1 (1-31)
in vitro. The enzymatic activity of recombinant mMCP-4 (rmMCP-4)
or peritonealmast cell derivedproteinswasmonitored via the hydrolysis
of the ﬂuorogenic substrate Suc-Ala-Ala-Pro-Phe-amidomethyl-couma-
rin whereas conversion of Big-ET-1 to ET-1 (1-31) by mMCP-4, in the
absence or in the presence of a speciﬁc chymase inhibitor, TY-
51469 (10 μM) was semi quantiﬁed by HPLC. In addition, the
impact of the deletion of the mMCP-4 gene on basal hemodynamic
parameters was assessed in WT or mMCP-4 KO mice chronically-
instrumented with wireless intra-aortic implanted pressure probes.
The rmMCP-4 and puriﬁedmast cell proteins fromWTmice possessed a
TY-51469-sensitive chymase-like activity. HPLC-detected production of
ET-1 (1-31) generated from the mMCP-4 (recombinant or mast
cell extracted)-dependent hydrolysis of Big-ET-1, was also abolished
by TY-51469. Finally, deletion of the mMCP-4 gene did not alter
basal hemodynamic measurements (MAP (mmHg) and HR (bpm):
106,5 ± 1,72 and 532,7 ± 25,13 or 107,5 ± 1,23 and 522,8 ± 15,91, in
WT ormMCP-4 KOmice, respectively). Our in vitro results demonstrate
that mast cells-derived mMCP-4 convert Big-ET-1 to ET-1 (1-31).
mMCP-4 however plays no signiﬁcant role on basal hemodynamic
parameters in conscious mice. Inhibiting mMCP-4 to reduce endoge-
nous ET-1 productionmay constitute a valid alternative to the targeting
of the endothelin-converting enzyme. (Supported by the Canadian
Institute for Health Research).
doi:10.1016/j.lfs.2013.12.132
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Endothelin-1, a 21-amino acid residue peptide, was ﬁrst isolated
as a potent vasoconstrictor peptide. Endothelin-1 is also known to
potentiate adrenal catecholamine secretion. In the present study, we
evaluated involvement of endothelin system in the catecholamine
release and synthesis in the adrenal gland. Expression of endothelin
receptors in the rat adrenal gland was conﬁrmed. Intravenous
infusion of endothelin-1 (1.0 nmol) increased blood pressure
(systolic and diastolic). Endothelin-1 stimulated intracellular calcium
changes, resulting in increased nuclear factor of T cell (NFAT) activity
and epinephrine release from cultured adrenal medullary cells.
Furthermore, endothelin-1 increased catecholamine synthesis and
caused hypertrophic changes in the cell size. Our results indicate
involvement of the endothelin system in the sympathetic regulation
of the adrenal medulla.
doi:10.1016/j.lfs.2013.12.133
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Introduction: The early hyperdynamic phase of sepsis is charac-
terized by imbalance between oxygen delivery (DO2) and consump-
tion (VO2) of the cells and microcirculatory insufﬁciencies. The role
of vasoconstriction in this process is complex and controversial, but
there are evidences for the activation of endothelin-A (ETA)
receptors in the pathomechanism. In this study we evaluated the
consequences of selective ETA receptor antagonism in a clinically
relevant rat model of sepsis. Methods: Groups 1 and 2 of Sprague
Dawley rats (n = 8 each) were subjected to fecal peritonitis (0.6 g/
kg autofeces i.p.), group 3 (n = 8) served as sham-operated control
(i.p. saline). In group 2, the ETA receptor antagonist ETR-p1/ﬂ
peptide (100 nmol/kg, iv) was given 17 h after the induction of
peritonitis. Invasive hemodynamic monitoring was started with
regular blood gas analyses between the 16–20 h of the insult to
calculate VO2–DO2 values. Xanthine oxidoreductase (XO) activity,
superoxide (SOX), and nitric oxide (NOx) production were deter-
mined from small intestine biopsies, whereas myeloperoxidase
(MPO) activity was measured from the lung tissue at the end of
the experiments. Results: The increased XO and MPO activities were
accompanied by elevated cardiac output and DO2, while VO2 de-
creased signiﬁcantly as compared to the control values (576.4 ml/min
vs 995.1 ml/min). The ETR-p1/ﬂ peptide treatment normalized the
DO2–VO2 values, increased NOx and reduced SOX levels, and decreased
XO and MPO activities. Conclusion: In the hyperdynamic phase of
sepsis, the inhibition of the vasoconstrictive ETA receptors maintains
cellular oxygen dynamics in the short run, and in parallel reduces
the activation level of the inﬂammatory cascade mechanisms. Grant
supports: OTKA K104656;TAMOP-4.2.2.A-11/1/KONV-2012-0035.
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